CX NEWS
Majority of CX audience decides endovascular-first strategy for critical limb ischaemia is a concept without evidence
At the CX Great Debate held yesterday, vascular and endovascular surgery titans went head-to-head to debate the contentious topic “Endovascular-first strategy for critical limb ischaemia is a concept without evidence”. Arguing in favour of [...]
Drug-coated balloon is “highly effective and safe” and shows outstanding clinical improvement for patients compared to an uncoated balloon
Ulf Teichgraeber The 12-month results from the full clinical cohort of the EffPAC randomised controlled trial, were presented for the first time at the CX Symposium yesterday. Target lesion revascularisation at 12 [...]
Paclitaxel-eluting stent fails BATTLE against bare metal stent
Yann Gouëffic The BATTLE trial comparing a drug-eluting stent (Zilver PTX, Cook) vs. a bare metal stent (Misago, Terumo) for the treatment of intermediate femoropopliteal lesions has failed to the show superiority [...]
EVRA (Early Venous Reflux Ablation) Ulcer Trial presented for the first time at the Charing Cross Symposium
Alun Davies, EVRA chief investigator Imperial College, London, United Kingdom
CX 2018: Record number of hands-on workshop opportunities for those technical tips and tricks!
This year, there are four CX Workshops that offer a record number of hands-on workshop opportunities for those technical tips and tricks. The CX Venous Workshop—which has now been running for 10 years—has more [...]
CX@CEC: Focus on challenging aortic disease
Rodney White This year’s annual China Endovascular Course (CEC; 2–5 November, Beijing, China) played host to the first CX@CEC session, in collaboration with the Charing Cross Symposium. Focused on complex aortic disease, [...]